TY - JOUR
T1 - Solifenacin treatment in men with overactive bladder
T2 - Effects on symptoms and patient-reported outcomes
AU - Kaplan, Steven A.
AU - Goldfischer, Evan R.
AU - Steers, William D.
AU - Gittelman, Marc
AU - Andoh, Masakazu
AU - Forero-Schwanhaeuser, Sergio
N1 - Funding Information:
This study was undertaken with a research grant from Astellas Pharma US Inc. and GlaxoSmithKline. Editorial support, including writing assistance, was provided by Thomas Gegeny MS, ELS, and Linda A. Goldstein, PhD, medical writers at Envision Scientific Solutions, and was funded by Astellas Pharma Global Development Inc. and GlaxoSmithKline.
PY - 2010/6
Y1 - 2010/6
N2 - Objective. In the few studies to evaluate antimuscarinics for overactive bladder (OAB) in men, safety has been the primary focus. In OAB efficacy trials, subject populations have been predominantly female and patient-reported outcomes (PROs) have been assessed only recently. We present a post hoc analysis of PRO-based findings from the subset of men (without presumed bladder outlet obstruction [BOO]) from two large, independent, open-label trials of solifenacin. Methods. Subjects with OAB for ≥3 months received flexibly dosed solifenacin for 12 weeks. At baseline and 4-week intervals, subjects completed the Patient Perception of Bladder Condition (PPBC) and Overactive Bladder Questionnaire (OAB-q). In one study, subjects also completed 3-day bladder diaries. At baseline, mean PPBC scores were similar in both studies and indicative of moderate-to-severe problems. Results. After 12 weeks of solifenacin, mean PPBC scores improved significantly (p<0.0001); values were suggestive of minor-to-moderate problems. Mean scores on the OAB-q were also significantly improved after solifenacin (p values ≤0.001). In men without presumed BOO, solifenacin significantly improved PRO measures of symptom bother, health-related quality of life, and overall perception of bladder problems. Conclusion. Results from these two studies support the use of solifenacin as a well-tolerated and efficacious treatment option for providing symptom relief in men with OAB without BOO.
AB - Objective. In the few studies to evaluate antimuscarinics for overactive bladder (OAB) in men, safety has been the primary focus. In OAB efficacy trials, subject populations have been predominantly female and patient-reported outcomes (PROs) have been assessed only recently. We present a post hoc analysis of PRO-based findings from the subset of men (without presumed bladder outlet obstruction [BOO]) from two large, independent, open-label trials of solifenacin. Methods. Subjects with OAB for ≥3 months received flexibly dosed solifenacin for 12 weeks. At baseline and 4-week intervals, subjects completed the Patient Perception of Bladder Condition (PPBC) and Overactive Bladder Questionnaire (OAB-q). In one study, subjects also completed 3-day bladder diaries. At baseline, mean PPBC scores were similar in both studies and indicative of moderate-to-severe problems. Results. After 12 weeks of solifenacin, mean PPBC scores improved significantly (p<0.0001); values were suggestive of minor-to-moderate problems. Mean scores on the OAB-q were also significantly improved after solifenacin (p values ≤0.001). In men without presumed BOO, solifenacin significantly improved PRO measures of symptom bother, health-related quality of life, and overall perception of bladder problems. Conclusion. Results from these two studies support the use of solifenacin as a well-tolerated and efficacious treatment option for providing symptom relief in men with OAB without BOO.
KW - Male
KW - Muscarinic antagonists
KW - Overactive
KW - Treatment outcome
KW - Urinary bladder
UR - http://www.scopus.com/inward/record.url?scp=77951835413&partnerID=8YFLogxK
U2 - 10.3109/13685530903440408
DO - 10.3109/13685530903440408
M3 - Article
C2 - 20001469
AN - SCOPUS:77951835413
SN - 1368-5538
VL - 13
SP - 100
EP - 107
JO - Aging Male
JF - Aging Male
IS - 2
ER -